Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

PURPOSE: We hypothesized that the addition of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Patients with recurrent or metastatic SCCHN wi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Argiris, Athanassios, Ghebremichael, Musie, Gilbert, Jill, Lee, Ju-Whei, Sachidanandam, Kamakshi, Kolesar, Jill M., Burtness, Barbara, Forastiere, Arlene A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2013
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3612594/
https://ncbi.nlm.nih.gov/pubmed/23460714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.45.4272
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia